Approval · Notice of Compliance 145 · 2004
PAROXETINE: Notice of Compliance 145
Issued February 5, 2004
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 145
- Date
- February 5, 2004
- Company
- Pro Doc LimiteeLaval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- New manufacturer and product name
- Therapeutic class
- Antidepressant, antiobsessional, antipanic, anxiolytic agent, social phobia (social anxiety disorder) therapy, posttraumatic stress disorder therapy
- Canadian reference product
- PAXIL (Smithkline Beecham Pharma, Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| PAROXETINE | 02248913 | Marketed |
| PAROXETINE | 02248914 | Marketed |
| PAROXETINE | 02248915 | Marketed |
Medicinal ingredients
- PAROXETINE HYDROCHLORIDE 10 MG per TAB
- PAROXETINE HYDROCHLORIDE 20 MG per TAB
- PAROXETINE HYDROCHLORIDE 30 MG per TAB